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Influenza virus is one of the most severe respiratory 
tract pathogens, annually causing substantial mor-
bidity, mortality, and economic loss. Influenza virus 
infection is usually self-limited in most instances, 
but it also causes several severe complications such 
as primary viral pneumonia, secondary bacterial 
pneumonia, myocarditis, and central nervous sys-
tem complications. These complications may be 
life-threatening and/or result in major sequelae, 
especially in the elderly, the immunocompromised 
hosts, and the patients with chronic illness.1
Currently, two classes of antiviral agents, the 
M2 ion channel inhibitors and neuraminidase (NA) 
inhibitors, have been used to treat influenza. The 
first class, adamantanes (amantadine and riman-
tadine), targets the proton ion channel formed by 
the viral M2 protein. Because this protein is absent 
in influenza B viruses, adamantanes have antiviral 
activity against influenza A viruses only. The NA 
inhibitors, including oseltamivir, are the only drugs 
possessing activity against both influenza A and 
influenza B viruses. These drugs are recommended 
to be used early in the disease course, usually no 
later than 2 days after the symptom onset. A recent 
report suggested antiviral therapy is beneficial for 
hospitalized patients even if being used after 2 days 
of symptom onset.2 Therefore, making a definite 
diagnosis of influenza virus infection is more im-
portant. In addition to viral culture, several rapid 
diagnostic tests have been developed.3,4 Reverse 
transcription polymerase chain reaction (RT-PCR) is 
preferred due to its speed, sensitivity, and specifi-
city, but it is not widely available to most clinicians. 
Enzyme immunoassay (EIA) rapid antigen detection 
is commercially available and is now used in some 
hospitals. The use of EIA is hindered by its low sen-
sitivity. The sensitivity of EIA is only 50−70% com-
pared with that of viral culture, and the specificity 
is close to 95%. Overall, a satisfactory rapid diagnos-
tic test to confirm influenza is still lacking.
Along with the increasing use of anti-influenza 
virus agents, the resistance to adamantanes and 
NA inhibitors has become a rising concern in recent 
years. In a global surveillance study, a significant 
increase in adamantane resistance was noted, from 
0.4% in 1994−1995 to 12.3% in 2003−2004.5 In the 
study, 84% of resistant viruses were obtained since 
the 2003 influenza season and, of those, 61% were 
collected from people in Asia. There was a sub-
stantial increase during 2002 to 2004 in China, 
Hong Kong, South Korea, and Taiwan. The rates of 
resistance were less than 10% before 2002 in these 
areas. Alarmingly, the frequencies of adamantane 
resistance after 2003 rose to 73.8% in China, 69.6% 
in Hong Kong, 15.1% in South Korea, and 22.7% in 
Taiwan. In another worldwide study surveying in-
fluenza A viruses isolated during 2004 to 2006, the 
overall resistance was 90.6% in H3N2 and 15.6% in 
H1N1.6 The rapid spread of adamantane resistance 
significantly diminishes its role in the treatment of 
influenza diseases. The resistance rate to NA inhib-
itors, oseltamivir and zanamivir, were reported to 
be low (0.33% for oseltamivir) in the 1999 to 2002.7 
In another study conducted in France, resistance 
to oseltamivir and/or zanamivir remained low at 
1% during 2005 and 2006.8 However, the rate of 
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oseltamivir resistance in the influenza A (H1N1) virus 
increased significantly from less than 1% before 
2007 to 8.6% during 2007 to 2008 in United States.9 
The recent growing resistance raises public health 
concerns and necessitates close monitoring of re-
sistance to NA inhibitors. During this flu season 
(2008−2009) in United States, the resistance rates 
of influenza A (H1N1) were 98.2% (162/165) to os-
eltamivir, 0% to zanamivir, and 1.2% (2/165) to ad-
amantanes.10 In contrast, the resistance rates of 
influenza A (H3N2) were 0% both to oseltamivir and 
zanamivir, but was 100% (37/37) to adamantanes. 
In influenza B, the NA inhibitor resistance remained 
0% (0/67). Therefore, the CDC of the United States 
issued interim recommendations for the use of an-
tiviral agents in the 2008−2009 flu season.11 When 
influenza A (H1N1) virus infection or exposure is sus-
pected, zanamivir or a combination of oseltamivir 
and rimantadine are more appropriate options than 
oseltamivir alone. This reinforced the importance 
of laboratory testing and local influenza surveil-
lance, which can help with physician decision-making 
regarding the choice of antiviral agents for their 
patients. During this flu season in Taiwan, the major 
type was influenza A virus, while H1N1 and H3N2 
were co-circulating during 2008−2009. The oseltami-
vir resistance rate of influenza A (H1N1) in Taiwan 
is also nearly 100%.12
In this issue of journal, Wang et al reported that 
51% of the influenza-like illness (ILI) patients were 
culture-confirmed influenza during the 2006−2007 
flu season.13 The high culture positive rate reported 
in this issue is remarkable. This indicates that in the 
influenza seasons or in an influenza epidemic, sud-
den onset fever with the acute respiratory infection 
symptoms in subjects younger than 18 years old is 
predictive of influenza virus infection. In Wang’s 
report, influenza B virus contributed 86.1% of the 
culture-confirmed influenza infection. This reflected 
the fact that there was an influenza B virus outbreak 
during 2006−2007 flu season in Taiwan. Wang et al 
also analyzed data that showed that leukopenia was 
found in 56.1% of children with influenza B virus 
infection in whom a blood test was performed. In 
those children infected with influenza B virus who 
had blood creatinine kinase (CK) tested, 56.5% had 
elevated CK and associated myalgia. In general, 
these findings are consistent with previous reports. 
Shen et al analyzed 274 influenza A and influenza B 
virus infected patients during 2005 to 2007. Children 
with influenza B infection tended to have lower leu-
kocytes counts and higher serum CK than those with 
influenza A infection.14 Influenza associated myosi-
tis (IAM) occurs mostly in influenza B infection.15,16 
Hu et al reported the rates of IAM were 5.5% and 
33.9% in influenza A and influenza B infections 
respectively. The proposed mechanism of IAM was 
direct muscle invasion by influenza virus, which was 
supported by the fact that the influenza virus was 
isolated from the muscle biopsy specimen from pa-
tients with IAM.17,18 However, the differences in the 
capabilities of influenza A and influenza B viruses to 
cause IAM remain unexplained. A glycoprotein (NB) 
encoded by RNA segment 6 is unique to the influenza 
B virus. The NB protein is an integral component of 
the membrane of influenza B virion. This unique NB 
protein may render influenza B virus more myotropic 
than influenza A virus. However, this hypothesis 
awaits further experimental confirmation.
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